Skip to main navigation

Investor Relations

Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Releases

Year

Jun 07, 2022

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

May 20, 2022

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

May 09, 2022

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 05, 2022

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

May 03, 2022

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Apr 26, 2022

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

Apr 19, 2022

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

Apr 19, 2022

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

Apr 06, 2022

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

Mar 10, 2022

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Investors & Media
Contact Us
Careers

Copyright © 2022 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap